Medicxi V
Medicxi
◆ Investment Thesis
Support companies with clear product visions to transform patient care, focusing on asset-focused biotechs across all stages of development via a capital-efficient investment strategy.
◆ About Medicxi
Medicxi is a leading European life sciences venture capital firm that employs a pioneering asset-centric investment model, creating and backing biotechnology companies focused on developing transformative therapies for patients. Medicxi V, a €500 million ($581 million) oversubscribed fund closed in November 2025, continues this strategy by supporting drug hunters and entrepreneurs in building asset-focused biotechs while also investing in existing companies at all development stages. The firm drives financial and intellectual resources toward single assets with clear product visions to maximize value creation.
◆ Sectors
◆ Stages
◆ Geography Focus
◆ Notable Investments
◆ Traits
Leads rounds
Co-invests
◆ FAQ
What does Medicxi V invest in?
Medicxi V invests in Biotech, Drug Discovery and Medtech at the growth, pre-seed, seed, series-a, series-b and series-c stages.
Which geographies does Medicxi V focus on?
Medicxi V focuses on Europe, and is headquartered in UK.
What is Medicxi V's typical check size?
Medicxi V typically writes checks of $1M to $20M.